Genesis Investment Management, LLP Zai Lab LTD Transaction History

Genesis Investment Management, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 18, 2024	SELL	$15.95 - $26.8 $7.6 Million - $12.8 Million	-476,540 Reduced 68.8%	216,123 $3.46 Million
Q4 2023 Jan 30, 2024	SELL	$22.97 - $30.58 $7.8 Million - $10.4 Million	-339,503 Reduced 32.89%	692,663 $18.9 Million
Q3 2023 Oct 17, 2023	SELL	$22.72 - $31.49 $7.27 Million - $10.1 Million	-320,056 Reduced 23.67%	1,032,166 $25.1 Million
Q2 2023 Jul 27, 2023	SELL	$25.3 - $39.67 $5.5 Million - $8.63 Million	-217,542 Reduced 13.86%	1,352,222 $37.5 Million
Q1 2023 May 02, 2023	BUY	$30.21 - $48.1 $2.41 Million - $3.84 Million	79,741 Added 5.35%	1,569,764 $52.2 Million
Q4 2022 Jan 20, 2023	BUY	$22.28 - $38.71 $1.62 Million - $2.81 Million	72,639 Added 5.12%	1,490,023 $45.7 Million
Q3 2022 Oct 21, 2022	SELL	$34.2 - $51.69 $6.59 Million - $9.97 Million	-192,790 Reduced 11.97%	1,417,384 $48.5 Million
Q2 2022 Jul 22, 2022	BUY	$23.14 - $49.68 $18.3 Million - $39.2 Million	789,822 Added 96.28%	1,610,174 $55.8 Million
Q1 2022 Apr 14, 2022	BUY	$27.77 - $64.4 $22.8 Million - $52.8 Million	820,352 New	820,352 $36.1 Million

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Genesis Investment Management, LLP, based on Form 13F filings with the SEC.

Stay updated on Genesis Investment Management, LLP with notifications on news.